◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksP › PSNL

Personalis Inc (PSNL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-09-13

Personalis Inc (PSNL) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Fremont, United States with about 259 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, PSNL reported $70M in revenue and ($81M) in net income.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Interactive charts & full statements → Open the PSNL valuation workbench →

PSNL Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Total Revenue$70M$70M$85M$73M$65M$85M$79M$65M$38M$9M
Gross Profit$9M$16M$27M$18M$13M$32M$20M$22M$12M($2M)
Gross Margin %12.7%22.7%31.7%24.8%20.5%37.0%25.6%33.9%31.2%-24.9%
Operating Income (EBIT)($114M)($88M)($68M)($96M)($116M)($65M)($42M)($22M)($14M)($22M)
Operating Margin %-164.1%-126.4%-80.7%-131.1%-177.6%-76.4%-53.6%-34.4%-36.4%-236.0%
Net Income($107M)($81M)($81M)($108M)($113M)($65M)($41M)($25M)($20M)($24M)
Net Margin %-153.8%-116.7%-96.1%-147.4%-174.2%-76.3%-52.5%-38.5%-52.6%-251.2%
EBITDA($97M)($71M)($70M)($97M)($105M)($59M)($35M)($19M)($15M)($21M)
Earnings Per Share (EPS)$-1.09$-0.91$-1.37$-2.25$-2.48$-1.49$-1.20$-1.39$-0.91$-1.08
Shares Outstanding (M)105M89M59M48M46M44M34M18M22M22M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PSNL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$22M$15M$17M$14M$17M$21M$17M$26M
Gross Profit$5M$0M$2M$2M$5M$7M$5M$9M
Gross Margin %21.2%1.8%10.9%13.2%27.7%35.0%27.1%34.0%
Operating Income (EBIT)($34M)($32M)($25M)($23M)($22M)($18M)($18M)($14M)
Operating Margin %-150.2%-207.9%-145.7%-160.7%-126.8%-85.9%-107.8%-55.9%
Net Income($32M)($30M)($24M)($22M)($20M)($16M)($16M)($39M)
Net Margin %-141.7%-194.1%-137.3%-149.4%-116.6%-76.4%-97.8%-152.0%
EBITDA($29M)($28M)($21M)($19M)($17M)($13M)($14M)($36M)
Earnings Per Share (EPS)$-0.30$-0.29$-0.26$-0.24$-0.23$-0.18$-0.23$-0.64
Shares Outstanding (M)105M104M92M89M89M87M73M61M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PSNL Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash from Operations (CFO)($92M)($75M)($45M)($56M)($70M)($71M)($43M)($18M)$6M$0M
Capital Expenditures (CapEx)$9M$5M$2M$11M$50M$11M$3M$8M$8M$5M
Free Cash Flow (FCF)($101M)($79M)($47M)($67M)($120M)($82M)($46M)($26M)($2M)($5M)
FCF Margin %-144.9%-114.1%-55.2%-91.4%-184.7%-95.8%-58.4%-40.6%-6.0%-51.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PSNL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($26M)($22M)($22M)($22M)($13M)($18M)($8M)($6M)
Capital Expenditures (CapEx)$4M$3M$0M$2M$0M$3M$1M$0M
Free Cash Flow (FCF)($30M)($26M)($22M)($23M)($13M)($20M)($9M)($6M)
FCF Margin %-132.2%-165.9%-128.7%-161.6%-76.9%-99.4%-53.8%-25.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PSNL Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Total Assets$312M$334M$270M$225M$293M$397M$245M$157M$42M$34M
Cash & Cash Equivalents$94M$124M$91M$57M$89M$106M$69M$55M$20M$23M
Total Liabilities$77M$73M$67M$96M$75M$86M$50M$51M$148M$126M
Total Debt (Short + Long-Term)$8M$8M$9M$9M$8M$6M$2M$1M$6M$18M
Total Shareholders' Equity$235M$261M$203M$129M$218M$310M$195M$107M($106M)($93M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PSNL viewer.

Other Companies in DIAGNOSTICS & RESEARCH

← PSNAll “P” companiesPSNY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.